Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023
- Written by PR Newswire
SOFIA, Bulgaria, June 20, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a pharmaceutical company that develops medicines for the treatment of allergy, asthma, ophthalmology and other autoimmune diseases, announced the preliminary phase I data of LP-003 (new generation of anti-IgE antibody) at the 29th...
Read more: Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023